Skip to Main Content

Patents and Contracts:

  • Hitendra S. Chand and Madhavan Nair: Long noncoding RNAs in pulmonary airway inflammation. A US Utility Patent #10,851,376 (Dec 01, 2020)
  • Walter Kisiel and Hitendra S. Chand: Human Kunitz-Type Inhibitor with Enhanced Antifibrinolytic Activity. A US Utility Patent #7,910,550.
  • Walter Kisiel, Hitendra S. Chand, and S. Paul Bajaj: Methods and Compositions for Plasmin Inhibition.  A US Utility Patent #7,585,842.
  • Walter Kisiel and Hitendra S. Chand: Human Kunitz-Type Inhibitor with Enhanced Antifibrinolytic Activity. A US Utility Patent #7,432,238.

Active Grants:

  • R21 AI152937 (NIAID, NIH), A LncRNA in Pulmonary Mucosal Immunity and HIV-Associated Comorbidities; 09/03/20-08/31/22; Role: Principal Investigator
  • 3R21 AI144374-02S1 (NIH/NIAID) “ Effects of SARS-CoV-2 Proteins on Airway Mucous Response and Associated LncRNAs”; 05/27/20-04/30/22; Role: Principal Investigator
  • R01 CA241752 (NCI, NIH) Targeting MUC5AC mucin in breast cancer brain metastasis; 02/01/21-01/31/26; Role: Consultant
  • R21 AI144374 (NIAID, NIH), Novel long noncoding RNAs in the airway mucous response; 05/16/19-04/30/22; Role: Principal Investigator
  • R01 HL149898 (NHLBI, NIH), Mechanisms of Defective Mitophagy and Cellular Senescence in HIV associated COPD; 07/15/19-06/30/23; Role: Co-Investigator